Thu, August 30, 2012
Wed, August 29, 2012
Tue, August 28, 2012
Mon, August 27, 2012
Sun, August 26, 2012
Sat, August 25, 2012
Fri, August 24, 2012
Thu, August 23, 2012
Wed, August 22, 2012
[ Wed, Aug 22nd 2012 ] - Market Wire
Inergetics Shareholder Update
Tue, August 21, 2012
Mon, August 20, 2012
[ Mon, Aug 20th 2012 ] - Market Wire
Watson Launches Generic Xopenex
Sat, August 18, 2012
Fri, August 17, 2012
Thu, August 16, 2012
Wed, August 15, 2012
Tue, August 14, 2012
Mon, August 13, 2012
Fri, August 10, 2012
Thu, August 9, 2012

Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcri


//health-fitness.news-articles.net/content/2012/ .. -c-and-sepsis-with-the-wall-street-transcri.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis... -- SAN DIEGO, Aug. 23, 2012 /PRNewswire/ --

Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript

[ ]

SAN DIEGO, Aug. 23, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Wall Street Transcript has conducted an interview with its Chairman and CEO, Jim Joyce. The full interview is now available to be accessed online at: [ http://aethlonmedical.investorroom.com/index.php?s=19 ].

(Photo: [ http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b ]) 

About Aethlon Medical, Inc.

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit [ www.aethlonmedical.com ].

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
[ jj@aethlonmedical.com ]

Jim Frakes
Chief Financial Officer
858.459.7800 x300
[ jfrakes@aethlonmedical.com ]

Marc Robins
877.276.2467
[ mr@aethlonmedical.com ]

SOURCE Aethlon Medical, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.aethlonmedical.com ]


Publication Contributing Sources